Matches in Wikidata for { <http://www.wikidata.org/entity/Q64183471> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q64183471 description "clinical trial" @default.
- Q64183471 description "ensayu clínicu" @default.
- Q64183471 description "klinisch onderzoek" @default.
- Q64183471 description "клінічне випробування" @default.
- Q64183471 name "A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Re" @default.
- Q64183471 type Item @default.
- Q64183471 label "A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Re" @default.
- Q64183471 prefLabel "A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Re" @default.
- Q64183471 P1132 Q64183471-6EC52EF4-D0FF-4FF9-93CB-1FD08C8715CB @default.
- Q64183471 P1476 Q64183471-08453C46-6C0B-4D72-A8B7-D242AF87EC76 @default.
- Q64183471 P17 Q64183471-19397605-261C-4463-A7C5-862796918E64 @default.
- Q64183471 P17 Q64183471-60177A9C-E4FE-4EB6-B5AF-758450048B0D @default.
- Q64183471 P17 Q64183471-6D6BBD13-B63F-496A-B652-B0C61457B77C @default.
- Q64183471 P17 Q64183471-97182DD8-21D8-40A0-9D79-356A6256B504 @default.
- Q64183471 P17 Q64183471-9F6EF396-A510-4668-A862-15F6BF4FDB3B @default.
- Q64183471 P17 Q64183471-CB0DA01A-0937-486D-B670-E3304B6DC668 @default.
- Q64183471 P3098 Q64183471-475ED0DB-6A17-456F-84B6-9420658A14F1 @default.
- Q64183471 P31 Q64183471-6FB60BA5-729E-4779-9720-611CB3672CDF @default.
- Q64183471 P4135 Q64183471-D3D5EEC6-F98B-447B-ACA9-AC8569F9212F @default.
- Q64183471 P580 Q64183471-20FBF3F3-D92E-4B60-AA7B-B4015207A9E9 @default.
- Q64183471 P582 Q64183471-08A8C97F-B827-4439-95F9-670CBECD1694 @default.
- Q64183471 P6099 Q64183471-E3154973-1747-4871-A1D0-0DDCE2AD5A16 @default.
- Q64183471 P6153 Q64183471-2F87761C-52A0-4B9E-BED3-40DA2C4CAB64 @default.
- Q64183471 P6153 Q64183471-49332E2C-4AD9-4268-B90C-918472BCFA93 @default.
- Q64183471 P6153 Q64183471-6330E43B-6579-4750-8E05-4C2AC33E867B @default.
- Q64183471 P6153 Q64183471-DA37A5DB-BA86-4074-AB1F-8DA234A61828 @default.
- Q64183471 P8363 Q64183471-1AA9DA97-FA31-4F8A-BF40-6313C9E2303B @default.
- Q64183471 P1132 "+7" @default.
- Q64183471 P1476 "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus" @default.
- Q64183471 P17 Q16 @default.
- Q64183471 P17 Q17 @default.
- Q64183471 P17 Q28 @default.
- Q64183471 P17 Q30 @default.
- Q64183471 P17 Q31 @default.
- Q64183471 P17 Q36 @default.
- Q64183471 P3098 "NCT03333317" @default.
- Q64183471 P31 Q30612 @default.
- Q64183471 P4135 "+36" @default.
- Q64183471 P580 "2017-11-24T00:00:00Z" @default.
- Q64183471 P582 "2018-03-23T00:00:00Z" @default.
- Q64183471 P6099 Q42824440 @default.
- Q64183471 P6153 Q115376 @default.
- Q64183471 P6153 Q6119635 @default.
- Q64183471 P6153 Q632891 @default.
- Q64183471 P6153 Q681025 @default.
- Q64183471 P8363 Q78089383 @default.